Company Growth (employees)
Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, US
Key People at Nektar Therapeutics
Robert Chess
Chairman of the Board
Jillian B. Thomsen
Senior Vice President, Finance and Chief Accounting Officer
Dorian Hirth
Senior Vice President, Human Resources and Facilities Operations
Timothy A. Riley
Senior Vice President, Technology Assessment and Quality Assurance
Nektar Therapeutics Office Locations
Nektar Therapeutics has offices in San Francisco, Huntsville and Hyderabad
San Francisco, US (HQ)
455 Mission Bay Boulevard South
Hyderabad, IN
Sy.Nos.101/2 Genome Valley Lalgadi Malakpet Shameerpet Mandal Rangareddy District Hyderabad
Huntsville, US
1112 Church Street
Nektar Therapeutics Data and Metrics
Nektar Therapeutics Financial Metrics
Nektar Therapeutics's revenue was reported to be $165.4 m in FY, 2016
USD
Revenue (FY, 2016) | 165.4 m |
Revenue growth (FY, 2015 - FY, 2016), % | (28%) |
Gross profit (FY, 2016) | 135.2 m |
Gross profit margin (FY, 2016), % | 82% |
Net income (FY, 2016) | (153.5 m) |
EBIT (FY, 2016) | (112.9 m) |
Market capitalization (27-Jun-2017) | 2.9 b |
Closing share price (27-Jun-2017) | 19.7 |
Cash (31-Dec-2016) | 59.6 m |
Nektar Therapeutics's current market capitalization is $2.9 b.
| USD | FY, 2013 | FY, 2014 | Y, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 148.9 m | 200.7 m | 230.8 m | 165.4 m |
Revenue growth, % | 35% | 15% | (28%) | |
Cost of goods sold | 38.5 m | 28.5 m | 34.1 m | 30.2 m |
Gross profit | 110.4 m | 172.2 m | 196.7 m | 135.2 m |
Gross profit Margin, % | 74% | 86% | 85% | 82% |
Operating expense total | 230.5 m | 188.7 m | 260.2 m | 278.3 m |
EBIT | (120.1 m) | (16.5 m) | (29.4 m) | (112.9 m) |
EBIT margin, % | (81%) | (8%) | (13%) | (68%) |
Interest expense | 18.5 m | 17.9 m | 18.3 m | 22.5 m |
Interest income | 732 k | 814 k | ||
Pre tax profit | (159.8 m) | |||
Income tax expense | 2.2 m | (512 k) | 506 k | 876 k |
Net Income | (162 m) | (53.9 m) | (81.2 m) | (153.5 m) |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 39.1 m | 12.4 m | 55.6 m | 59.6 m |
Inventories | 13.5 m | 13 m | 11.3 m | 11.1 m |
Current Assets | 257.9 m | 288.2 m | 350.1 m | 426.3 m |
PP&E | 67 m | 70.4 m | 71.3 m | 65.6 m |
Goodwill | 76.5 m | 76.5 m | 76.5 m | 76.5 m |
Total Assets | 434.5 m | 441.6 m | 502.1 m | 568.9 m |
Accounts Payable | 9.1 m | 2.7 m | 2.4 m | 2.8 m |
Current Liabilities | 98.2 m | 64 m | 61.2 m | 72.2 m |
Additional Paid-in Capital | 1.6 b | 1.8 b | 1.9 b | 2.1 b |
Retained Earnings | (1.7 b) | (1.8 b) | (1.9 b) | (2 b) |
Total Equity | (89.9 m) | 36.3 m | 6.4 m | 88.1 m |
Financial Leverage | -4.8 x | 12.2 x | 78.1 x | 6.5 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (162 m) | (53.9 m) | (81.2 m) | (153.5 m) |
Depreciation and Amortization | 14.3 m | 12.9 m | 12.9 m | 15.4 m |
Accounts Receivable | 3.6 m | (1.4 m) | (16 m) | 4.3 m |
Inventories | 4.8 m | 500 k | 1.6 m | 237 k |
Accounts Payable | 6.2 m | (6.4 m) | (412 k) | 518 k |
Cash From Operating Activities | (38.5 m) | (142 m) | (73.1 m) | (117 m) |
Purchases of PP&E | (4.1 m) | (10 m) | (11.2 m) | (6.4 m) |
Cash From Investing Activities | 49.9 m | (37.6 m) | (14.3 m) | (82.4 m) |
Cash From Financing Activities | 2.2 m | 153 m | 130.8 m | 203.6 m |
Interest Paid | 17.6 m | 17.4 m | 20.2 m | 20.6 m |
Income Taxes Paid | 1 m | 964 k | 860 k | 757 k |
| USD | Y, 2016 |
|---|---|
Revenue/Employee | 269 k |
Financial Leverage | 6.5 x |
